Short Interest in Sunshine Biopharma, Inc. (NASDAQ:SBFM) Drops By 54.1%

Sunshine Biopharma, Inc. (NASDAQ:SBFM) was the target of a large decline in short interest in the month of December. As of December 31st, there was short interest totalling 217,900 shares, a decline of 54.1% from the December 15th total of 474,300 shares. Currently, 8.0% of the shares of the company are short sold. Based on an average daily trading volume, of 666,100 shares, the short-interest ratio is presently 0.3 days.

Sunshine Biopharma Price Performance

Sunshine Biopharma stock traded down $0.06 during midday trading on Tuesday, hitting $2.83. The company’s stock had a trading volume of 42,046 shares, compared to its average volume of 196,505. Sunshine Biopharma has a 1-year low of $2.11 and a 1-year high of $571.20. The company has a 50-day moving average price of $2.82 and a two-hundred day moving average price of $2.37. The company has a market cap of $3.46 million, a price-to-earnings ratio of -0.02 and a beta of 1.32.

Sunshine Biopharma (NASDAQ:SBFM) last issued its earnings results on Tuesday, November 5th. The company reported ($0.94) EPS for the quarter, missing the consensus estimate of $9.00 by ($9.94). The firm had revenue of $8.44 million during the quarter. Sunshine Biopharma had a negative net margin of 12.82% and a negative return on equity of 17.89%.

Analyst Upgrades and Downgrades

Separately, Aegis reaffirmed a “buy” rating and set a $15.00 target price on shares of Sunshine Biopharma in a report on Thursday, December 5th.

About Sunshine Biopharma

Sunshine Biopharma, Inc, a pharmaceutical company, focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates in two segments, Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products.